rat tfa Search Results


secretin (33-59), rat tfa  (TargetMol)
N/A
   Buy from Supplier
hank  (MedChemExpress)
94
MedChemExpress hank
Hank, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rat+tfa/%CE%B1-CGRP/pmc12774734-245-12-25
Average 94 stars, based on 1 article reviews
hank - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
orexin a  (MedChemExpress)
93
MedChemExpress orexin a
tDCS promotes the expression of OXA and OX1R in TBI rats. ( A ) Representative western blotting images <t>of</t> <t>Orexin-A</t> and Orexin-A receptor 1 (OX1R) on 14 days post-TBI. Using GAPDH as an internal reference for band density normalization ( n = 3). ( B ) Quantification of western blotting for Orexin-A expression ( n = 3). ( C ) Quantification of western blotting for OX1R expression ( n = 3). ( D ) Representative immunofluorescence images of OX1R expression in brain tissue ( n = 3). ( E ) Quantification of immunofluorescence for OX1R expression ( n = 3). ( F ) Quantitative analysis of mRNA levels of OX1R expression ( n = 3). Results are expressed as means ± standard deviation, the statistical significance of differences was evaluated by One-way ANOVA, * represents the comparison between the Sham group and the TBI group, # signifies the comparison between the TBI group and the tDCS group, and & denotes the comparison between the tDCS group and the Sham-tDCS group. P < 0.05 indicates statistical significance.
Orexin A, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rat+tfa/Orexin+A/pmc11042948-154-7-8
Average 93 stars, based on 1 article reviews
orexin a - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
β amyloid 1 42 peptides  (MedChemExpress)
94
MedChemExpress β amyloid 1 42 peptides
tDCS promotes the expression of OXA and OX1R in TBI rats. ( A ) Representative western blotting images <t>of</t> <t>Orexin-A</t> and Orexin-A receptor 1 (OX1R) on 14 days post-TBI. Using GAPDH as an internal reference for band density normalization ( n = 3). ( B ) Quantification of western blotting for Orexin-A expression ( n = 3). ( C ) Quantification of western blotting for OX1R expression ( n = 3). ( D ) Representative immunofluorescence images of OX1R expression in brain tissue ( n = 3). ( E ) Quantification of immunofluorescence for OX1R expression ( n = 3). ( F ) Quantitative analysis of mRNA levels of OX1R expression ( n = 3). Results are expressed as means ± standard deviation, the statistical significance of differences was evaluated by One-way ANOVA, * represents the comparison between the Sham group and the TBI group, # signifies the comparison between the TBI group and the tDCS group, and & denotes the comparison between the tDCS group and the Sham-tDCS group. P < 0.05 indicates statistical significance.
β Amyloid 1 42 Peptides, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rat+tfa/%CE%B2-Amyloid/pmc11786345-30-0-12
Average 94 stars, based on 1 article reviews
β amyloid 1 42 peptides - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
mog 35 55 peptide  (MedChemExpress)
94
MedChemExpress mog 35 55 peptide
tDCS promotes the expression of OXA and OX1R in TBI rats. ( A ) Representative western blotting images <t>of</t> <t>Orexin-A</t> and Orexin-A receptor 1 (OX1R) on 14 days post-TBI. Using GAPDH as an internal reference for band density normalization ( n = 3). ( B ) Quantification of western blotting for Orexin-A expression ( n = 3). ( C ) Quantification of western blotting for OX1R expression ( n = 3). ( D ) Representative immunofluorescence images of OX1R expression in brain tissue ( n = 3). ( E ) Quantification of immunofluorescence for OX1R expression ( n = 3). ( F ) Quantitative analysis of mRNA levels of OX1R expression ( n = 3). Results are expressed as means ± standard deviation, the statistical significance of differences was evaluated by One-way ANOVA, * represents the comparison between the Sham group and the TBI group, # signifies the comparison between the TBI group and the tDCS group, and & denotes the comparison between the tDCS group and the Sham-tDCS group. P < 0.05 indicates statistical significance.
Mog 35 55 Peptide, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rat+tfa/MOG/pmc13288803-35-18-26
Average 94 stars, based on 1 article reviews
mog 35 55 peptide - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
pacap  (MedChemExpress)
92
MedChemExpress pacap
tDCS promotes the expression of OXA and OX1R in TBI rats. ( A ) Representative western blotting images <t>of</t> <t>Orexin-A</t> and Orexin-A receptor 1 (OX1R) on 14 days post-TBI. Using GAPDH as an internal reference for band density normalization ( n = 3). ( B ) Quantification of western blotting for Orexin-A expression ( n = 3). ( C ) Quantification of western blotting for OX1R expression ( n = 3). ( D ) Representative immunofluorescence images of OX1R expression in brain tissue ( n = 3). ( E ) Quantification of immunofluorescence for OX1R expression ( n = 3). ( F ) Quantitative analysis of mRNA levels of OX1R expression ( n = 3). Results are expressed as means ± standard deviation, the statistical significance of differences was evaluated by One-way ANOVA, * represents the comparison between the Sham group and the TBI group, # signifies the comparison between the TBI group and the tDCS group, and & denotes the comparison between the tDCS group and the Sham-tDCS group. P < 0.05 indicates statistical significance.
Pacap, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rat+tfa/PACAP+(1-27)%2C+human%2C+ovine%2C+rat/pm38418876-592-29-33
Average 92 stars, based on 1 article reviews
pacap - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier
nmu  (MedChemExpress)
92
MedChemExpress nmu
tDCS promotes the expression of OXA and OX1R in TBI rats. ( A ) Representative western blotting images <t>of</t> <t>Orexin-A</t> and Orexin-A receptor 1 (OX1R) on 14 days post-TBI. Using GAPDH as an internal reference for band density normalization ( n = 3). ( B ) Quantification of western blotting for Orexin-A expression ( n = 3). ( C ) Quantification of western blotting for OX1R expression ( n = 3). ( D ) Representative immunofluorescence images of OX1R expression in brain tissue ( n = 3). ( E ) Quantification of immunofluorescence for OX1R expression ( n = 3). ( F ) Quantitative analysis of mRNA levels of OX1R expression ( n = 3). Results are expressed as means ± standard deviation, the statistical significance of differences was evaluated by One-way ANOVA, * represents the comparison between the Sham group and the TBI group, # signifies the comparison between the TBI group and the tDCS group, and & denotes the comparison between the tDCS group and the Sham-tDCS group. P < 0.05 indicates statistical significance.
Nmu, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rat+tfa/Neuromedin+U%2C+rat/pm39681141-78-16-19
Average 92 stars, based on 1 article reviews
nmu - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier
mch(human, mouse, rat) tfa  (Aladdin Scientific Corporation)
N/A
MCH (human, mouse, rat) TFA is a potent peptide agonist of MCH-R and exhibits binding IC 50 values of 0.3nM and 1.5 nM for MCH1R and MCH2R, respectively. MCH (human, mouse, rat) is a highly
   Buy from Supplier
secretin (33-59), rat tfa  (Aladdin Scientific Corporation)
N/A
Secretin (33-59), rat (TFA) is a 27-aa peptide, which acts on secretin receptor , and enhances the secretion of bicarbonate, enzymes, and K + from the pancreas.Appearance:SolidIC50& Target:Secretin receptorBiological Activity:Secretin (33-59), rat (TFA) is a
   Buy from Supplier
[leu31,pro34]-neuropeptide y(human,rat) tfa  (TargetMol)
N/A
   Buy from Supplier
gip, rat tfa  (TargetMol)
N/A
   Buy from Supplier
angiotensin i-13c6,15n (human, mouse, rat) tfa  (TargetMol)
N/A
   Buy from Supplier

Image Search Results


tDCS promotes the expression of OXA and OX1R in TBI rats. ( A ) Representative western blotting images of Orexin-A and Orexin-A receptor 1 (OX1R) on 14 days post-TBI. Using GAPDH as an internal reference for band density normalization ( n = 3). ( B ) Quantification of western blotting for Orexin-A expression ( n = 3). ( C ) Quantification of western blotting for OX1R expression ( n = 3). ( D ) Representative immunofluorescence images of OX1R expression in brain tissue ( n = 3). ( E ) Quantification of immunofluorescence for OX1R expression ( n = 3). ( F ) Quantitative analysis of mRNA levels of OX1R expression ( n = 3). Results are expressed as means ± standard deviation, the statistical significance of differences was evaluated by One-way ANOVA, * represents the comparison between the Sham group and the TBI group, # signifies the comparison between the TBI group and the tDCS group, and & denotes the comparison between the tDCS group and the Sham-tDCS group. P < 0.05 indicates statistical significance.

Journal: Aging (Albany NY)

Article Title: Transcranial direct current stimulation promotes angiogenesis and improves neurological function via the OXA-TF-AKT/ERK signaling pathway in traumatic brain injury

doi: 10.18632/aging.205724

Figure Lengend Snippet: tDCS promotes the expression of OXA and OX1R in TBI rats. ( A ) Representative western blotting images of Orexin-A and Orexin-A receptor 1 (OX1R) on 14 days post-TBI. Using GAPDH as an internal reference for band density normalization ( n = 3). ( B ) Quantification of western blotting for Orexin-A expression ( n = 3). ( C ) Quantification of western blotting for OX1R expression ( n = 3). ( D ) Representative immunofluorescence images of OX1R expression in brain tissue ( n = 3). ( E ) Quantification of immunofluorescence for OX1R expression ( n = 3). ( F ) Quantitative analysis of mRNA levels of OX1R expression ( n = 3). Results are expressed as means ± standard deviation, the statistical significance of differences was evaluated by One-way ANOVA, * represents the comparison between the Sham group and the TBI group, # signifies the comparison between the TBI group and the tDCS group, and & denotes the comparison between the tDCS group and the Sham-tDCS group. P < 0.05 indicates statistical significance.

Article Snippet: In order to investigate the influence of Orexin-A (MedChemExpress, USA, HY-106224) on TNF-α (Abbkine, USA, PRP1013)-induced HUVEC cells and explore potential mechanisms, we subjected the cells to varying concentrations of Orexin-A (0.1, 0.5, and 1 μM), TNF-α (10 ng/mL), and the inhibitor LY3214996 (MedChemExpress, HY-101494) of the ERK1/2 signal transduction pathway (1 μM).

Techniques: Expressing, Western Blot, Immunofluorescence, Standard Deviation, Comparison

Orexin-A improved scratch wound healing and angiogenesis of TNF-α-injured HUVEC cells. ( A ) The image shows the effect of Orexin-A (TO1: 0.1 μM, TO2: 0.5 μM and TO3: 1 μM) on wound healing of TNF-α (10 ng/ml) injured cells. ( B ) Quantification of Orexin-A on wound closure ( n = 3). ( C ) Representative images of the study effects of TNF-α (10 ng/ml) and the three concentrations (TO1: 0.1, TO2: 0.5 and TO3: 1 μM) of Orexin-A on tube formation. ( D ) Quantification of the effects of Orexin-A on the number of capillary-like tubes in TNF-α-treated cells ( n = 3). Results are expressed as means ± standard deviation, the statistical significance of differences was evaluated by One-way ANOVA, * denotes the comparison between the Sham group and the TBI group, # represents the comparison between the TBI and the Sham-tDCS group, & signifies the comparison between the tDCS group and the Sham-tDCS group, and ¥ indicates the comparison between the tDCS group and the tDCS+SB334867 group. P < 0.05 indicates statistical significance.

Journal: Aging (Albany NY)

Article Title: Transcranial direct current stimulation promotes angiogenesis and improves neurological function via the OXA-TF-AKT/ERK signaling pathway in traumatic brain injury

doi: 10.18632/aging.205724

Figure Lengend Snippet: Orexin-A improved scratch wound healing and angiogenesis of TNF-α-injured HUVEC cells. ( A ) The image shows the effect of Orexin-A (TO1: 0.1 μM, TO2: 0.5 μM and TO3: 1 μM) on wound healing of TNF-α (10 ng/ml) injured cells. ( B ) Quantification of Orexin-A on wound closure ( n = 3). ( C ) Representative images of the study effects of TNF-α (10 ng/ml) and the three concentrations (TO1: 0.1, TO2: 0.5 and TO3: 1 μM) of Orexin-A on tube formation. ( D ) Quantification of the effects of Orexin-A on the number of capillary-like tubes in TNF-α-treated cells ( n = 3). Results are expressed as means ± standard deviation, the statistical significance of differences was evaluated by One-way ANOVA, * denotes the comparison between the Sham group and the TBI group, # represents the comparison between the TBI and the Sham-tDCS group, & signifies the comparison between the tDCS group and the Sham-tDCS group, and ¥ indicates the comparison between the tDCS group and the tDCS+SB334867 group. P < 0.05 indicates statistical significance.

Article Snippet: In order to investigate the influence of Orexin-A (MedChemExpress, USA, HY-106224) on TNF-α (Abbkine, USA, PRP1013)-induced HUVEC cells and explore potential mechanisms, we subjected the cells to varying concentrations of Orexin-A (0.1, 0.5, and 1 μM), TNF-α (10 ng/mL), and the inhibitor LY3214996 (MedChemExpress, HY-101494) of the ERK1/2 signal transduction pathway (1 μM).

Techniques: Standard Deviation, Comparison

Orexin-A enhanced HUVEC angiogenesis and wound healing through TF-AKT/ERK pathway. ( A ) Representative images depicting the combined administration of LY3214996 (1 μM) and Orexin-A (0.5 μM) on wound healing effects. ( B ) The quantification of scratch assay results for each group is shown, measuring the closure of scratch gaps ( n = 3). ( C ) Representative images illustrating the impact of the combined administration of LY3214996 (1 μM) and Orexin-A (0.5 μM) on vascular formation. ( D ) Displays the quantification of tube formation assay results for each group, calculating the number of formed tubes ( n = 3). ( E ) Representative gross morphology of Matrigel in situ ( n = 3). ( F ) Representative H&E-stained images of matrix plug sections ( n =3). ( G ) Representative immunofluorescence images of CD31-positive cells within matrix plugs. ( H ) Quantitative analysis of the proportion of CD31-positive cells within matrix plugs ( n = 3). Results are expressed as means ± standard deviation, the statistical significance of differences was evaluated by One-way ANOVA, * denotes the comparison between the Sham group and the TBI group, # represents the comparison between the TBI and the Sham-tDCS group, & signifies the comparison between the tDCS group and the Sham-tDCS group, and ¥ indicates the comparison between the tDCS group and the tDCS+SB334867 group. P < 0.05 indicates statistical significance.

Journal: Aging (Albany NY)

Article Title: Transcranial direct current stimulation promotes angiogenesis and improves neurological function via the OXA-TF-AKT/ERK signaling pathway in traumatic brain injury

doi: 10.18632/aging.205724

Figure Lengend Snippet: Orexin-A enhanced HUVEC angiogenesis and wound healing through TF-AKT/ERK pathway. ( A ) Representative images depicting the combined administration of LY3214996 (1 μM) and Orexin-A (0.5 μM) on wound healing effects. ( B ) The quantification of scratch assay results for each group is shown, measuring the closure of scratch gaps ( n = 3). ( C ) Representative images illustrating the impact of the combined administration of LY3214996 (1 μM) and Orexin-A (0.5 μM) on vascular formation. ( D ) Displays the quantification of tube formation assay results for each group, calculating the number of formed tubes ( n = 3). ( E ) Representative gross morphology of Matrigel in situ ( n = 3). ( F ) Representative H&E-stained images of matrix plug sections ( n =3). ( G ) Representative immunofluorescence images of CD31-positive cells within matrix plugs. ( H ) Quantitative analysis of the proportion of CD31-positive cells within matrix plugs ( n = 3). Results are expressed as means ± standard deviation, the statistical significance of differences was evaluated by One-way ANOVA, * denotes the comparison between the Sham group and the TBI group, # represents the comparison between the TBI and the Sham-tDCS group, & signifies the comparison between the tDCS group and the Sham-tDCS group, and ¥ indicates the comparison between the tDCS group and the tDCS+SB334867 group. P < 0.05 indicates statistical significance.

Article Snippet: In order to investigate the influence of Orexin-A (MedChemExpress, USA, HY-106224) on TNF-α (Abbkine, USA, PRP1013)-induced HUVEC cells and explore potential mechanisms, we subjected the cells to varying concentrations of Orexin-A (0.1, 0.5, and 1 μM), TNF-α (10 ng/mL), and the inhibitor LY3214996 (MedChemExpress, HY-101494) of the ERK1/2 signal transduction pathway (1 μM).

Techniques: Wound Healing Assay, Tube Formation Assay, In Situ, Staining, Immunofluorescence, Standard Deviation, Comparison